Patel headshotPrincipal Investigator: Dr. Jyoti D. Patel

Research Institution: University of Chicago

Disease: Non-small cell lung cancer

Research Description: Lung cancer is the most deadly cancer in the U.S. for both men and women, and clinical research is especially critical to find treatments. Equally important is uncovering the biological mechanisms to determine why a patient may or may not respond to treatment. The research team is conducting a Phase 1 clinical research trial in non-small cell lung cancer (NSCLC), combining cancer immunotherapy drugs Ipilimumab and Nivolumab, originally approved for use in melanoma, with targeted radiation therapy. This project seeks to confirm the safety of this combination treatment in patients and identify any improvement in patient response compared to the current standard of treatment. Samples also will be collected and analyzed to identify biological changes that can then be correlated with patient response. Deeper knowledge of the relationship between radiation therapy and available cancer immunotherapies has the potential to inform many future combination therapies for lung cancer treatment and many cancer types.

CWR funding role: Participating funder

CWR Start date: June 2017

Sign up for our eNewsletter today!


First Name

Cures Within Reach


All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes.  CWR is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Wednesday the 21st. Copyright 2018 Cures Within Reach.